Among the 175 significantly differentially expressed genes, we identified TAGLN2 as an upregulated gene in IDH1/2 WT grade II and III gliomas compared to IDH1/2 mutant tumors (p-value=7.73×10−5; FDR=0.053) in our institutional cohort (Figure 1A). The gene discussed is TAGLN2; the disease is central nervous system cancer.